- Home
- ICU vs PHGE Comparison
ICU vs PHGE Comparison
Compare ICU & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICU
- PHGE
- Stock Information
- Founded
- ICU 2018
- PHGE 2015
- Country
- ICU United States
- PHGE Israel
- Employees
- ICU N/A
- PHGE N/A
- Industry
- ICU Biotechnology: Pharmaceutical Preparations
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- ICU Health Care
- PHGE Health Care
- Exchange
- ICU Nasdaq
- PHGE Nasdaq
- Market Cap
- ICU 10.4M
- PHGE 11.0M
- IPO Year
- ICU N/A
- PHGE N/A
- Fundamental
- Price
- ICU $0.32
- PHGE $0.49
- Analyst Decision
- ICU
- PHGE Strong Buy
- Analyst Count
- ICU 0
- PHGE 1
- Target Price
- ICU N/A
- PHGE $15.00
- AVG Volume (30 Days)
- ICU 1.2M
- PHGE 278.8K
- Earning Date
- ICU 08-12-2025
- PHGE 08-13-2025
- Dividend Yield
- ICU N/A
- PHGE N/A
- EPS Growth
- ICU N/A
- PHGE N/A
- EPS
- ICU N/A
- PHGE N/A
- Revenue
- ICU $428,000.00
- PHGE N/A
- Revenue This Year
- ICU $754.07
- PHGE N/A
- Revenue Next Year
- ICU $100.09
- PHGE N/A
- P/E Ratio
- ICU N/A
- PHGE N/A
- Revenue Growth
- ICU N/A
- PHGE N/A
- 52 Week Low
- ICU $0.31
- PHGE $0.34
- 52 Week High
- ICU $13.85
- PHGE $3.86
- Technical
- Relative Strength Index (RSI)
- ICU 10.59
- PHGE 51.35
- Support Level
- ICU $0.31
- PHGE $0.34
- Resistance Level
- ICU $1.30
- PHGE $0.51
- Average True Range (ATR)
- ICU 0.10
- PHGE 0.05
- MACD
- ICU -0.09
- PHGE 0.01
- Stochastic Oscillator
- ICU 1.11
- PHGE 77.53
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).